Lincoln Pharmaceuticals Ltd
NSE: LINCOLN BSE: 531633
₹654.30
(6.25%)
Fri, 13 Feb 2026, 03:17 pm
Market Cap12.29B
PE Ratio16.38
Dividend0.29
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1979
- M/s.Lincoln Pharmaceuticals was established as a partnership firm with Mr. Rajni G. Patel, Mr. Hasmukhbhai I.Patel, Mrs. Hansaben A.Patel, Mrs. Jivtiben C.Patel, Mrs. Jiviben T.Patel and Mrs. Lilaben T. Patel as partners.
1981
- Mr.Mihir V. Patel, Mr.Maheshbhai M.Patel, Mr.Yogeshkumar I. Patel and Mrs.Madhuben V.Patel were admitted as Partners.
1995
- The Company was incorporated as a public limited company by converting partnership concern M/s. Lincoln Pharmaceuticals under Part IX of the Companies Act 1956.
- All the properties of the firm and all the liabilities of the firm vested in the Company.
2000
- The company has signed agreements with NSDL & CDSL for dematerialisation.
2003
- The Joint Director of General Govt of India has given the certificate of recognition of Export House to the company.
- Lincoln Pharmaceuticals introduces AIDS Drugs
- Launched US FDA approved drug Gatifloxacin.
- Launched PROLIN - NATURAL
- Lincoln Pharmaceuticals Ltd has informed that it has launched a new drug under the brand name of 'Namsafe'.
- Lincoln Pharmaceuticals Ltd has delists equity shares from Delhi Stock Exchange Association Ltd
2005
- Lincoln Pharmaceuticals secures export order from England, UK
2006
- Lincoln Pharma introduces Nozzled Liquid formulations
- Lincoln Pharmaceuticals secures order from Republic Democratic of Congo
- Lincoln Pharmaceuticals introduces Vivian Roll On in Novel Drug Delivery System
- The Company has signed agreement with Russian firm M/s. Fortune Impex Ltd for marketing Company's manufactured products in Russia.
- Company has splits its Face value of Shares from Rs 10 to Rs 2
2007
- Lincoln Pharmaceuticals recommends final Dividend @ 12%
2008
- Lincoln Pharmaceuticals recommends final Dividend @ 12%
2009
- Lincoln Pharmaceuticals has incorporated new Company namely M/s. Zullinc Healthcare Ltd as wholly owned subsidiary Company of Lincoln Pharmaceuticals Ltd.
- Company has Consolidates its Face value of Shares from Rs 2 to Rs 10
2010
- Lincoln Pharmaceuticals Ltd. gains market share with technologically advanced Collagen Bio-tech products
2011
- Lincoln Pharmaceuticals wins patent for a Novel Nasal Drug delivery system introduces India's first Nasal Spray treatment for Vomiting.
- Lincoln Pharmaceuticals Ltd. introduces India's first Long-Acting Paracetamol 'Pa-12' for Long term relief from Fever and Pain
- Lincoln Pharmaceuticals Ltd launches Antimalarial drug 'ARH 1' developed with innovative dose optimization technology, for the first time in the world.
- Lincoln Pharmaceuticals Ltd. launches Ayurvedic Product 'ISL Granules' to serve mother and child healthcare segment.
- Lincoln Pharmaceuticals has acquired/purchased 62 Lacs equity shares of M/s. Lincoln Parenteral Ltd and by virtue of said acquisition/purchase of equity share, M/s. Lincoln Parenteral Ltd has become subsidiary Company
2012
- Lincoln Pharmaceuticals has recommended the payment of Dividend @ Rs. 0.60/- per equity share (6%) on face value of Rs. 10/- each
2013
- Lincoln Pharmaceuticals has recommended the payment of Dividend of Rs. 0.60 (@ 6%) per equity share of face value Rs. 10/- each.
2014
- Lincoln Pharmaceuticals Ltd has launched an Ultramodern State of Art plant for Injectable.
- Company has commended the payment of Dividend of Rs. 0.60/- per equity share (@ 6%) of face value of Rs. 10/- each of the Company.
2015
- The company has successfully launched a cough syrup called Namcold DX which contains Dextromethorphan Polistrirex.
2016
- Lincoln Pharmaceuticals launches Vaginal Spray for FIRST TIME IN INDIA.
2020
- Lincoln Pharma gets Gujarat food & drug regulator nod to manufacture COVID-19 drugs.
- The company has received approval from the state regulator to manufacture varied dosages of HCQ tablets and HCQ sulfate tablets among others at Khatraj plant.
2021
- The company received approval for the company's manufacturing facility from Australia's medicines and medical devices regulator.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800